Evidence map›Paper›PMID 35142156›Full record

ArticleHaematologica2022

The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.

Sachiko Kanaji, Yosuke Morodomi, Hartmut Weiler, Alessandro Zarpellon, Robert R Montgomery, Zaverio M Ruggeri, Taisuke Kanaji

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Application of genetic testing for the diagnosis of von Willebrand disease.Journal of thrombosis and haemostasis : JTH · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sachiko KanajiDepartment of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee. skana@scripps.edu.
Yosuke MorodomiDepartment of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla.
Hartmut WeilerBlood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee.
Alessandro ZarpellonDepartment of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego.
Robert R MontgomeryBlood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee, WI; Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226.
Zaverio M RuggeriDepartment of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego.
Taisuke KanajiDepartment of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee.
Scripps Research Institute · USVersiti Blood Center of Wisconsin · USMedical College of Wisconsin · US

Funding

Transgenic/Knockout CoreP01HL044612 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 1990 to 2015
$33.4M
Human Tyr-tRNA Synthetase as a Potent Effector of MegakaryocytopoiesisR01HL129011 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI KANAJI, TAISUKE · 2016 to 2019
$1.9M
NHLBI NIH HHS P01 HL044612NHLBI NIH HHS R01 HL129011
6 · The paper itself

Abstract

Type 2B von Willebrand disease (VWD) is caused by gain-of-function mutations in von Willebrand factor (VWF). Increased VWF affinity for GPIba results in loss of high molecular weight multimers and enhanced platelet clearance, both contributing to the bleeding phenotype. Severity of the symptoms vary among type 2B VWD patients, with some developing thrombocytopenia only under stress conditions. Efforts have been made to study underlying pathophysiology for platelet abnormalities, but animal studies have been limited because of species specificity in the VWF-GPIba interaction. Here, we generated a severe form of type 2B VWD (p.V1316M) knockin mice in the context of human VWF exon 28 (encoding A1 and A2 domains) and crossed them with human GPIba transgenic strain. Heterozygous mutant mice recapitulated the phenotype of type 2B VWD in autosomal dominant manner and presented severe macrothrombocytopenia. Of note, platelets remaining in the circulation had extracytoplasmic GPIba shed-off from the cell surface. Reciprocal bone marrow transplantation determined mutant VWF produced from endothelial cells as the major cause of the platelet phenotype in type 2B VWD mice. Moreover, altered megakaryocyte maturation in the bone marrow and enhanced extramedullary megakaryopoiesis in the spleen were observed. Interestingly, injection of anti-VWF A1 blocking antibody (NMC-4) not only ameliorated platelet count and GPIba expression, but also reversed MK ploidy shift. In conclusion, we present a type 2B VWD mouse model with humanized VWF-GPIba interaction which demonstrated direct influence of aberrant VWF-GPIba binding on megakaryocytes.

Indexed as

Thrombocytopeniavon Willebrand Diseasesvon Willebrand Disease, Type 2AnimalsBlood PlateletsEndothelial CellsHumansMicePlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factoradhesion receptorPlatelet Glycoprotein GPIb-IX Complexvon Willebrand Factor

Identifiers

PMID35142156
PMCPMC9425322
OpenAlexW4211157005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.